Immunocore Holdings

Immunocore Holdings Plc operates as a holding company. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Earnings data Q4 2020

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Immunocore to present at the 40 th Annual J.P. Morgan Healthcare Conference

Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 6 December 2021) Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announces the initial Phase 1 data of IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in selected advanced solid tumors.

Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4

Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update

Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel

Immunocore announces publication of phase 3 data comparing tebentafusp with investigator's choice in The New England Journal of Medicine

Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial

Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021

Immunocore Announces UK's Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

The U.S. and European Union regulators have accepted for review Immunocore Holdings Plc's (NASDAQ: IMCR) marketing applications seeking approval for tebentafusp for uveal melanoma (eye cancer). Related:  Newly Listed Immunocore's Tebentafusp Receives Breakthrough Therapy Tag For Eye Cancer.

Immunocore's Eye Cancer Candidate Under Priority Review In US, Europe

Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update

Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B

Immunocore Reports First Quarter 2021 Financial Results

Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Affirm

Roblox

Coinbase's IPO was spectacular. But these stocks with recent IPOs might have better long-term prospects.

3 Recent IPO Stocks That Could Be Bigger Winners Than Coinbase

Immunocore presents phase 3 data comparing tebentafusp with investigator's choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting

Immunocore is a "platform" pharmaceutical company looking to help naïve T cells recognize and kill their targets. Their technology involves soluble TCRs that recognize markers that indicate whether a cell is cancerous or infected with a virus.

Immunocore: 'Off-The-Shelf' T Cell Therapy

Immunocore Provides Business Update and Reports Full Year 2020 Financial Results

Phase 3 data comparing tebentafusp (IMCgp100) with investigator's choice subject of oral plenary Phase 3 data comparing tebentafusp (IMCgp100) with investigator's choice subject of oral plenary

Immunocore Announces Upcoming Presentations at the American Association for Cancer Research (AACR) 2021 Annual Meeting

The FDA has designated Breakthrough Therapy status to Immunocore Holdings PLC's (NASDAQ: IMCR) tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive in adult patients with unresectable or metastatic uveal melanoma (mUM), cancer of the eye involving the iris, ciliary body, or choroid. In an initial pre-planned interim analysis of Phase 3 trial (IMCgp100-202) in previously untreated metastatic uveal melanoma, tebentafusp demonstrated superior overall survival benefit as a monotherapy.

Newly Listed Immunocore's Tebentafusp Receives Breakthrough Therapy Tag For Eye Cancer

The stock price of Immunocore Holdings plc (NASDAQ: IMCR) increased by 66.15% on Friday, February 5. This is why it happened.

IMCR Stock Price Increased 66.15%: Why It Happened

Angion Biomedica

Atotech

Bolt Biotherapeutics

Landos Biopharma

Lucira Health

ON24

Pharvaris B.V.

Sana Biotechnology

Sensei Biotherapeutics

Terns Pharmaceuticals

TELUS International (Cda)

Vor Biopharma

The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. German chemicals group Atotech downsized and priced below the range to raise $498 million at a $3.3 billion market cap.

U.S. IPO Weekly Recap: Biotechs Flood The IPO Market In A 14 IPO Week

A flock of biotech companies are opening for trading Friday. Most of the deals grew in size, with price increases as well.

The Biotech IPO Wave Continues. Here Are 7 Stocks Hitting the Market.

News for Immunocore Holdings Stock (IMCR)